Healio3h
FDA clears investigational new drug application for Zabalafin Hydrogel
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
Endocrinology Advisor18h
Dupilumab in Atopic Dermatitis: Favorable Cardiometabolic Profile Confirmed
Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.
verywellhealth1d
Why People Are Rubbing Beef Tallow on Their Skin—Does It Work?
If you’re considering beef tallow for skincare, it may help with dry skin due to its fatty acid content, which supports ...
aad.org2d
We let everyone know. No one knows skin, hair, and nails like a dermatologist.
Traditional and social media efforts are paying off.
aad.org2d
AADA educates employers about the value of dermatologic care
The AADA continues to increase awareness among employers of the impact skin conditions have on employee health, productivity, ...
Healio2d
Nemluvio approved in EU, UK, Switzerland for atopic dermatitis, prurigo nodularis
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
Medscape2d
European Commission Approves Nemolizumab for Atopic Dermatitis and Prurigo Nodularis
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...
The Pharma Letter3d
Galderma doubles up on Nemluvio approvals
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...
PMLiVE3d
EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
Galderma's Nemluvio® (Nemolizumab) Granted Marketing Authorization In The United Kingdom And Switzerland For Moderate-To...
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...
Pharmabiz3d
UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis
UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...